Holen Sie sich die Stockscreener-App
17.18
0.23%
0.04
Handel nachbörslich:
17.18
Centessa Pharmaceuticals Plc Adr Aktie (CNTA) Neueste Nachrichten
Bank of New York Mellon Corp Buys Shares of 10,257 Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) - Defense World
The Future of Centessa Pharmaceuticals plc ADR: Analyzing CNTA - investchronicle.com
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares By Investing.com - Investing.com India
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares - Investing.com
Cerity Partners LLC Invests $471,000 in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) - Defense World
Centessa Pharmaceuticals plc ADR Inc. (CNTA) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Taseko Mines Ltd: Navigating Market Fluctuations with a 1.09B Market Cap - investchronicle.com
Codere Online Luxembourg (NASDAQ:CDRO) & Take-Two Interactive Software (NASDAQ:TTWO) Critical Analysis - Defense World
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Buy” by Analysts - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.8% After Insider Selling - Defense World
Centessa Pharma (CNTA) CBO Weinhoff sells $138k in shares - Investing.com
Centessa Pharma CEO Saha sells $694,826 in shares - Investing.com
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders - MarketScreener
Centessa Pharmaceuticals plc Announces Clearance of Investigational New Drug Application for ORX142 - MarketScreener
SEC Form N-CSRS filed by abrdn Life Sciences Investors Shares of Beneficial Interest - Quantisnow
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet - MSN
Centessa Pharmaceuticals Announces Executive Changes By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals Announces Executive Changes - Investing.com India
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 Net Loss $0.20 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 License and Other Revenue of $15M - marketscreener.com
Is Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) A Suitable Stock For New Investors Today? - Stocksregister
Ratios in Focus: Analyzing Centessa Pharmaceuticals plc ADR (CNTA)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Investor’s Delight: Centessa Pharmaceuticals plc ADR (CNTA) Closes Weak at 13.50, Down -1.53 - DWinneX
Was Centessa Pharmaceuticals plc ADR (CNTA)’s session last reading good? - uspostnews.com
Top investors say Centessa Pharmaceuticals plc ADR (CNTA) ticks everything they need - Sete News
Investor’s Toolkit: Key Ratios for Assessing MSCI Inc (MSCI)’s Performance - DWinneX
Financial Metrics Check: Centessa Pharmaceuticals plc ADR (CNTA)’s Ratios for Trailing Twelve Months - DWinneX
Should investors be concerned about Centessa Pharmaceuticals plc ADR (CNTA)? - uspostnews.com
Parsons Corp (PSN) Shares Up Despite Recent Market Volatility - News Heater
Lantheus Holdings Inc [LNTH] Insider Activity: An Update for Investors - knoxdaily.com
Piper Sandler Initiates Centessa Pharmaceuticals at Overweight With $38 Price Target - MarketScreener
Centessa Pharmaceuticals chief business officer sells $163,386 in stock - Investing.com
Centessa Pharmaceuticals CEO sells shares worth $918,060 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CEO sells shares worth $918,060 - Investing.com India
Centessa Pharmaceuticals CAO sells shares worth $120,205 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CAO sells shares worth $120,205 - Investing.com India
Centessa Pharmaceuticals’ general counsel sells $98,697 in stock - Investing.com
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - Stocks Register
Ratios Revealed: Decoding Centessa Pharmaceuticals plc ADR (CNTA)’s Financial Health - The Dwinnex
Hemophilia Market Insights: Key Trends and Developments Across Different Types of Hemophilia | DelveInsight - GlobeNewswire Inc.
Centessa Pharmaceuticals officer sells shares worth $588,943 - Investing.com India
Aegon Ltd (AEG) looking to reclaim success with recent performance - SETE News
Adversity is less terrifying than hope: Wayfair Inc (W) - SETE News
Perhaps timely catching Autolus Therapeutics plc ADR (AUTL) would be a good idea - SETE News
Taking the lead: Centessa Pharmaceuticals plc ADR (CNTA) - SETE News
Centessa Pharmaceuticals plc ADR (CNTA) Shares Up Despite Recent Market Volatility - The News Heater
Centessa Pharmaceuticals officer Tia Bush sells $185,406 in shares - Investing.com
A closer look at Centessa Pharmaceuticals plc ADR (CNTA) is warranted - US Post News
Centessa Pharmaceuticals chief business officer sells shares worth $193,429 - Investing.com India
Form N-CSR FIDELITY CONCORD STREET For: Nov 30 - StreetInsider.com
Centessa Pharmaceuticals general counsel Hussain Iqbal sells $91,740 in shares - Investing.com
Centessa Pharmaceuticals appoints new Chief Medical Officer - Investing.com
Centessa Pharmaceuticals' chief business officer sells shares worth $170,399 - Investing.com
Centessa Pharmaceuticals CEO sells $959,057 in shares - Investing.com
Centessa Pharmaceuticals general counsel sells shares for $1.27 million - Investing.com
Wake Up to This Biotech Stock That Still Has Big Potential Upside - MarketBeat
Biotech Soars, And Then Dives, On $5 Billion Opportunity - Investor's Business Daily
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics - Yahoo Finance
SRPT Stock Quote Price and Forecast - CNN
0.71%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):